Water 3: Aquablation Outcomes for Prostate Volumes >150ML VS Prostate Volumes <150ML at a Single Community Institution

Document Type

Conference Proceeding

Publication Date

5-2024

Publication Title

Journal of Urology

Abstract

INTRODUCTION AND OBJECTIVE: Aquablation for benign prostatic hyperplasia in clinical trials has been reported in prostate volumes up to 150mL. The objective of this study was to compare Aquablation outcomes in patient's pre-operative (preop) prostate volumes (PV) greater than 150 mL to patients with prostate volumes less than 150 mL. METHODS: Retrospective chart review from September of 2018 to 2022 at a single institution. Variables collected included adverse events (AE) with Clavian-Dindo grades, transfusion rates, surgical retreatment rates, continued medication use post operatively (postop), and American Urologic Association symptom scores (AUASS) with Quality-of-Life indicator (QOL). The Aquablations were then stratified by preop PV<150 ml (PV<150) and ≥150 ml(PV≥150). Independent sample T-Test and Chi-square test were used for data analysis (SPSS 28.0). RESULTS: 174 men treated with Aquablation were included, of these 18 patients were excluded from analysis due to no recorded PV. Thus, 156 patients were included in the analysis: 133 with PV<150 and 33 with PV≥150. PV<150 and PV≥150 were well matched with respect to age in years (72.03 vs 73.09 p[0.396), BMI (27.93 vs 29.38p[0.226), preop hemoglobin (13.92 vs 13.83 p[0.805), and preop retention (17.2% vs 21.2% p[0.596). There was no significant difference between the groups with respect to length of stay, adverse events, blood transfusion, AUASS/QOL preop and postop, postop Qmax, and postop alpha blocker use (Table 1). PV<150 had 18 AE (14.6%), 2 AE Clavian-Dindo ≥3. PV≥150 had 7 AE (21.2%), 1 AE Clavian-Dindo ≥3.PV<150 compared to PV≥150 had lower retreatment rates (10.7% vs24.2% p[0.043), postop hemoglobin drop (1.54 vs 2.45 p[0.004),postop use of finasteride (8.9% vs 31.3% p[0.001), and shorter OR times in minutes (57.01 vs 71.58 p[<0.001). CONCLUSIONS: Aquablation therapy for prostate volumes ≥150 ml appears to have similar safety and subjective urinary outcomes compared to prostate volumes <150 ml. However, Aquablation for prostate volumes ≥150 ml had surgical retreatment rates of 24.2% and post operative finasteride use of 31.3% in our cohort.

Volume

211

Issue

5S

First Page

e1020

Comments

American Urological Association Annual Meeting, May 3-6, 2024, San Antonio, TX

DOI

10.1097/01.JU.0001008904.63948.3b.01

Link to Full Text

Share

COinS